LENS FOGGING COMPROMISES 3 OUT OF 4 OR 77% OF ALL SURGERIES
Every minute an endoscope fogs, the operating room loses time and money, but also increases safety risks:
Root Causes:
ONE APPLICATION. 3+ HOURS OF CRYSTAL-CLEAR SURGERY
KnoxFog™ FDA-Cleared Industry Leading Anti-Fog Gel for endoscopes.
Uninterupted Surgeries
No need to withdrawal scope during surgery
Efficiency Gains
Saves hospitals up to $24K per 3 Hour procedure
Clinically Proven Safe
FDA-cleared, sterile, biocompatible
Plug and Play Simplicity
One “dip, wipe, and go” step
KnoxFog™ Sterile Anti-Fog Gel
SUPERIOR PERFORMANCE AT 90% LOWER COST
30× longer clarity than competitors with a single application
COST COMPARISON TABLE
| Procedure Length | KnoxFog | Competitor 1 | Competitor 2 |
|---|---|---|---|
| 1-Hours | $150 (1 application) | $60-$90 (3-4 applications) | $540 (4 applications) |
| 2-Hours | $150 (1 application) | $120-$180 (6-8 applications) | $1000 (8 applications) |
| 3-Hours | $150 (1 application) | $180-$270 (9-12 applications) | $1620 (12 applications) |
ADDRESSING A $266B U.S. MEDICAL DEVICE MARKET
KnoxFog’s clinically validated effectiveness positions it as a critical innovation within the fast-growing medical devices and endoscopy markets. KnoxFog addresses a critical pain point in 77% of all surgeries, within the fast-growing $24.7B global endoscopy equipment market (CAGR 7.6%).
At $150 per procedure = $8.7B annual opportunity
• Rising surgical procedure volumes
• Increasing adoption of minimally invasive surgery
• Growing hospital focus on OR efficiency
KNOXFOG ADDRESSES A CRITICAL SURGICAL NEED IN A GROWING MARKET
FOUR SALES CHANNELS READY TO LAUNCH
UV ONE’s powerhouse sales team ensures a strong entry into the market. Our team is firmly established in the VA Hospital procurement system with a strong track record of VA sales. Our team is also recognized for their sales achievements in the non-government healthcare sales space.
Four sales channels are ready to launch with highly experienced specialized medical sales teams ready to go as soon as manufacturing begins.
MEDICAL TECHNOLOGY IN RESEARCH AND DEVELOPMENT
PEER REVIEWED MEDICAL IP
ClearRetina, is a biocompatible hyper hydrophilic gel used to prevent fogging in retina surgeries in patients who have had cataract surgery.
InnovaStrip™ currently in R&D, is a low volume, fast, accurate, handheld comprehensive Small Volume Blood Diagnostics (SVBD) testing unit. Used at intake, it yields simultaneously more accurate & comprehensive blood diagnostics for electrolytes (Na‚ Mg‚ Ca‚ Cl‚ K‚ Ca)‚ metals (Fe‚ Cu‚ Se‚ I)‚ toxins (As‚ Cd‚ Hg‚ Pb)‚ and radio-nuclides (87Sr‚ 131I‚ 235U‚ 239 Pu) in one test within minutes.
InnovaBug, currently in R&D, is a low volume, fast and accurate handheld blood analysis unit for pathogen detection. By detecting the presence of pathogens in blood the user can determine the best course of treatment and eliminating overuse of antibiotic’s and ensuring proper treatment is started.
SURFACE ENERGY INNOVATION BEYOND MEDICAL
INDUSTRIAL & INDUSTRIAL AND ENERGY APPLICATIONS
Surface Energy Engineering (SEE™) for a Sustainable Future. At UV ONE, we’re at the forefront of innovation, adapting cutting-edge surface energy engineering to produce substantial solutions for many industry sectors.
Behind every successful company are the dedicated professionals who make it happen. Our diverse team brings together decades of experience, innovative thinking, and a shared commitment to excellence. From R&D, science, physics and engineering to quality assurance, each team member contributes unique expertise that helps drive our success.
Get to know the individuals who work tirelessly to deliver the solutions you can trust. We believe that great teams build great products, and we’re proud to introduce you to ours.
Dora Suppes CEO, Co-Founder: Veteran in healthcare and tech commercialization with 40+ years of leadership.
Dora’s expertise in sterilization and anti-fog coatings, combined with her ability to navigate the complex FDA clearance process, was instrumental in establishing UV One and its vision to make advanced medical technologies universally accessible.
Mark Russell-Hill COO, Co-Founder: Optical systems engineer and inventor with deep expertise in light and surface energy.
Mark bridges technical innovation with scalable operations. His meticulous operational processes and systems-thinking were instrumental in scaling UV One’s technology from laboratory innovation to market success.
Cisco Schipperheijn, CTO, Co-Founder: Is recognized for his strategic vision and technical expertise in developing disruptive technologies with long-term viability.
Serial technology executive specializing in disruptive medical and diagnostic devices. Cisco brings strategic foresight and technical rigor, ensuring long-term defensibility and predictable ROI.
Dr. Nicole Herbots, CSO: Consults on laboratory research, device design, and the transition of innovations. into full-scale FDA-approved manufacturing.
Dr. Herbots has founded over a dozen medical device companies built on her patented technologies, with expertise spanning anti-fog coatings, diagnostic devices, and bio-compatible implant surfaces.
Contact Us
Learn more about our technologies: